(SIGA) SIGA Technologies - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8269171067
Antiviral, Smallpox, TPOXX, Health Security
Dividends
| Dividend Yield | 9.60% |
| Yield on Cost 5y | 11.63% |
| Yield CAGR 5y | 15.47% |
| Payout Consistency | 98.8% |
| Payout Ratio | 57.9% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 59.6% |
| Value at Risk 5%th | 87.7% |
| Relative Tail Risk | -10.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | -11.87 |
| CAGR/Max DD | 0.02 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.425 |
| Beta | 0.664 |
| Beta Downside | 0.425 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.39% |
| Mean DD | 31.68% |
| Median DD | 33.25% |
Description: SIGA SIGA Technologies October 24, 2025
SIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage biopharma focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.
Key metrics as of the latest filing (Q2 2024): cash and short-term investments of roughly $140 million, a net loss of $32 million for the trailing twelve months, and a market-cap near $350 million. The company’s revenue is driven almost entirely by government contracts for TPOXX, which together with the broader biodefense budget (projected to grow at ~4% CAGR) constitute its primary economic driver.
Sector trends that affect SIGA include heightened federal spending on pandemic preparedness and the expanding “health-security” niche, which has attracted increased R&D incentives and potential partnership opportunities with defense contractors.
For a deeper, data-rich analysis of SIGA’s valuation and peer landscape, you may find ValueRay’s research tools helpful.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (74.5m TTM) > 0 and > 6% of Revenue (6% = 10.3m TTM) |
| FCFTA 0.50 (>2.0%) and ΔFCFTA 13.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 117.8% (prev 91.17%; Δ 26.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.50 (>3.0%) and CFO 116.6m > Net Income 74.5m (YES >=105%, WARN >=100%) |
| Net Debt (-171.0m) to EBITDA (94.3m) ratio: -1.81 <= 3.0 (WARN <= 3.5) |
| Current Ratio 9.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (71.6m) change vs 12m ago -0.23% (target <= -2.0% for YES) |
| Gross Margin 76.29% (prev 78.34%; Δ -2.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 80.69% (prev 88.93%; Δ -8.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -29.47 (EBITDA TTM 94.3m / Interest Expense TTM -3.18m) >= 6 (WARN >= 3) |
Altman Z'' 6.76
| (A) 0.88 = (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m |
| (B) -0.16 = Retained Earnings (Balance) -37.6m / Total Assets 231.6m |
| (C) 0.44 = EBIT TTM 93.7m / Avg Total Assets 213.5m |
| (D) -1.34 = Book Value of Equity -37.6m / Total Liabilities 28.1m |
| Total Rating: 6.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.60
| 1. Piotroski 4.50pt |
| 2. FCF Yield 43.18% |
| 3. FCF Margin 67.52% |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda -1.81 |
| 6. ROIC - WACC (= 25.38)% |
| 7. RoE 35.26% |
| 8. Rev. Trend -24.84% |
| 9. EPS Trend -10.74% |
What is the price of SIGA shares?
As of December 11, 2025, the stock is trading at USD 6.25 with a total of 640,350 shares traded.
Over the past week, the price has changed by +0.16%, over one month by -3.99%, over three months by -28.33% and over the past year by +6.68%.
Over the past week, the price has changed by +0.16%, over one month by -3.99%, over three months by -28.33% and over the past year by +6.68%.
Is SIGA a buy, sell or hold?
SIGA Technologies has no consensus analysts rating.
What are the forecasts/targets for the SIGA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.5 | 180.5% |
| Analysts Target Price | 17.5 | 180.5% |
| ValueRay Target Price | 6.4 | 2.7% |
SIGA Fundamental Data Overview December 10, 2025
Market Cap USD = 440.4m (440.4m USD * 1.0 USD.USD)
P/E Trailing = 5.9709
P/E Forward = 5.6275
P/S = 2.5568
P/B = 2.182
Beta = 0.997
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 269.4m USD (440.4m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
FCF Yield = 43.18% (FCF TTM 116.3m / Enterprise Value 269.4m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.16 (Enterprise Value 269.4m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 23.82% (-1.99m / -8.36m)
NOPAT = 71.4m (EBIT 93.7m * (1 - 23.82%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.15% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 33.82% (NOPAT 71.4m / Invested Capital 211.2m)
WACC = 8.44% (E(440.4m)/V(441.3m) * Re(8.46%) + (debt cost/tax rate unavailable))
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 80.10% ; FCFE base≈98.4m ; Y1≈121.4m ; Y5≈207.0m
Fair Price DCF = 45.37 (DCF Value 3.25b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -10.74 | EPS CAGR: -78.27% | SUE: -0.51 | # QB: 0
Revenue Correlation: -24.84 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0
EPS next Year (2026-12-31): EPS=1.51 | Chg30d=-0.080 | Revisions Net=-1 | Growth EPS=+297.4% | Growth Revenue=+132.4%
P/E Trailing = 5.9709
P/E Forward = 5.6275
P/S = 2.5568
P/B = 2.182
Beta = 0.997
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 269.4m USD (440.4m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
FCF Yield = 43.18% (FCF TTM 116.3m / Enterprise Value 269.4m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.16 (Enterprise Value 269.4m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 23.82% (-1.99m / -8.36m)
NOPAT = 71.4m (EBIT 93.7m * (1 - 23.82%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 32.15% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 33.82% (NOPAT 71.4m / Invested Capital 211.2m)
WACC = 8.44% (E(440.4m)/V(441.3m) * Re(8.46%) + (debt cost/tax rate unavailable))
Discount Rate = 8.46% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.36%
[DCF Debug] Terminal Value 80.10% ; FCFE base≈98.4m ; Y1≈121.4m ; Y5≈207.0m
Fair Price DCF = 45.37 (DCF Value 3.25b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -10.74 | EPS CAGR: -78.27% | SUE: -0.51 | # QB: 0
Revenue Correlation: -24.84 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0
EPS next Year (2026-12-31): EPS=1.51 | Chg30d=-0.080 | Revisions Net=-1 | Growth EPS=+297.4% | Growth Revenue=+132.4%
Additional Sources for SIGA Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle